Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma

International Journal of Pharmaceutics

Volumn 490, Issue 1-2, 2015, Pages 85-93

  Belletti, D ^a   Tosi, G ^a   Riva, G ^b   Lagreca, I ^b   Galliania, M ^a   Luppi, M ^b   Vandelli, M A ^a   Forni, F ^a   Ruozi, B ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Anti Syndecan 1 engineered nanoparticles; Cell cycle; Liposomes; Nutlin 3; PLGA nanoparticles; Primary effusion lymphoma

Indexed keywords

BROXURIDINE; LIPOSOME; NANOCARRIER; NUTLIN 3; SYNDECAN 1; ANTINEOPLASTIC AGENT; DRUG CARRIER; IMIDAZOLE DERIVATIVE; NANOPARTICLE; PIPERAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DENSITY; CELL ENCAPSULATION; CELL VIABILITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CYTOFLUOROMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHYSICAL CHEMISTRY; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; ZETA POTENTIAL; APOPTOSIS; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; LYMPHOMA, PRIMARY EFFUSION; PARTICLE SIZE; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMIDAZOLES; LIPOSOMES; LYMPHOMA, PRIMARY EFFUSION; NANOPARTICLES; PARTICLE SIZE; PIPERAZINES; S PHASE;

EID: 84929992931     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.05.029     Document Type: Article

References (25)

1. G.L. Bond, W. Hu, and A.J. Levine MDM2 is a central node in the p53 pathway: 12 years and counting Curr. Cancer Drug Targets 5 2005 3 8
2. L. Bondioli, L. Costantino, A. Ballestrazzi, D. Lucchesi, D. Boraschi, F. Pellati, S. Benvenuti, G. Tosi, and M.A. Vandelli PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid Biomaterials 31 2010 3395 3403
3. M. Das, and S.K. Sahoo Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy Acta Biomater. 7 2011 355 369
4. E. Drakos, A. Thomaides, L.J. Medeiros, J. Li, V. Leventaki, M. Konopleva, M. Andreeff, and G.Z. Rassidakis Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma Clin. Cancer Res. 13 2007 3380 3387
5. A. Fahr, and X. Liu Drug delivery strategies for poorly water-soluble drugs Expert Opin. Drug Deliv. 4 2007 403 416
6. O.C. Farokhzad, and R. Langer Impact of nanotechnology on drug delivery ACS Nano 27 2009 16 20
7. J. Jass, T. Tjärnhage, and G. Puu From liposomes to supported, planar bilayer structures on hydrophilic and hydrophobic surfaces: an atomic force microscopy study Biophys. J. 79 2000 3153 3163
8. D.P. Joshi, Y.L. Lan-Chun-Fung, and J.W. Pritchard Determination of polyvinylalcohol via its complex with boric acid and iodine Anal. Chim. Acta 104 1979 153 160
9. S. Kiortosis, K. Kachrimanis, T. Broussali, and S. Malamataris Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component Eur. J. Pharm. Biopharm. 59 2005 73 83
10. K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia Blood 108 2006 993 1000
11. Y. Liu, K. Li, J. Pan, B. Liu, and S.S. Feng Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel Biomaterials 31 2010 330 338
12. A.R. Mohammed, N. Weston, A.G. Coombes, M. Fitzgerald, and Y. Perrie Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability Int. J. Pharm. 285 2004 23 34
13. M.G. Nava-Arzaluz, E. Piñón-Segundo, A. Ganem-Rondero, and D. Lechuga-Ballesteros Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles Recent Pat. Drug Deliv. Formul. 6 2012 209 223
14. L. Nobs, F. Buchegger, R. Gurny, and E. Allemann Surface modification of poly-lactide acid nanoparticles by covalent attachment of thiol groups by means of three methods Int. J. Pharm. 250 2003 327 337
15. C.E. Petre, S.H. Sin, and D.P. Dittmer Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy J. Virol. 81 2006 1912 1922
16. B. Ruozi, G. Riva, D. Belletti, G. Tosi, P. Barozzi, M. Luppi, F. Forni, and M.A. Vandelli Immunoliposomal systems targeting the primary effusion lymphoma (PEL): in vitro study Nanomedicine (UK) 5 2010 1051 1064
17. B. Ruozi, G. Tosi, F. Forni, M. Fresta, and M.A. Vandelli Atomic force microscopy and photon correlation spectroscopy: two techniques for rapid characterization of liposomes Eur. J. Pharm. Sci. 25 2005 81 89
18. G. Sarek, S. Kurki, J. Enbäck, G. Iotzova, J. Haas, P. Laakkonen, M. Laiho, and P.M. Ojala Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas J. Clin. Invest. 117 2007 1019 1028
19. G. Sarek, and P.M. Ojala p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas Cell Cycle 15 2007 2205 2209
20. T.R. Tice, and R.M. Gilley Preparation of injectable controlled-release microcapsules by solvent-evaporation process J. Control. Release 2 1985 343 352
21. G. Tosi, L. Costantino, F. Rivasi, B. Ruozi, E. Leo, A.V. Vergoni, R. Tacchi, A. Bertolini, M.A. Vandelli, and F. Forni Targeting CNS: in vivo experiments with peptide derivatized nanoparticles loaded with loperamide and rhodamine 123 J. Control. Release 122 2007 1 9
22. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E.A. Liu In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
23. R. Voltan, P. Secchiero, B. Ruozi, L. Caruso, F. Forni, M. Palomba, G. Zauli, and M.A. Vandelli Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53 (wild-type) JVM-2 but not towards p53 (mutated) BJAB leukemic cells Curr. Med. Chem. 20 2013 2712 2722
24. R. Voltan, P. Secchiero, B. Ruozi, F. Forni, C. Agostinis, L. Caruso, M.A. Vandelli, and G. Zauli Nanoparticles engineered with Rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts Clin. Cancer Res. 19 2013 3871 3880
25. A. Wicki, D. Witzigmann, V. Balasubramanian, and J. Huwyler Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications J. Control. Release 28 2015 138 157